ArticleJournal of the American Heart Association2026
Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular outflow tract obstruction is a major contributor to morbidity in hypertrophic cardiomyopathy and an established therapeutic target. However, the risk factors driving progression to symptomatic heart failure in asymptomatic patients with obstructive hypertrophic cardiomyopathy remain incompletely understood.
methodsWe retrospectively identified 341 consecutive asymptomatic patients with obstructive hypertrophic cardiomyopathy (New York Heart Association class I, left ventricular ejection fraction >50%, left ventricular outflow tract gradient ≥30 mm Hg) across 4 centers between 2003 and 2023 (mean±SD age, 48±17 years; 78% men). All underwent transthoracic echocardiography and cardiovascular magnetic resonance. A combined adverse end point included progression to New York Heart Association class II or greater or development of systolic dysfunction (left ventricular ejection fraction <50%). Univariate and multivariable Cox regression analyses were performed.
resultsOver 4.4 (range, 2.4-7.0) years, 98 patients (29%) experienced New York Heart Association progression (6.6%/year). Of these patients, 34 (35%) underwent septal reduction therapy, 4 (4%) developed end-stage heart failure without intervention, and 2 (2%) developed left ventricular ejection fraction <50%. Independent multivariable predictors of the adverse end point were impaired right ventricular stroke volume index, female sex, and prior atrial fibrillation. Patients with progression had lower right ventricular stroke volume index (37±12 versus 42±11 mL/m
conclusionsAmong asymptomatic patients with obstructive hypertrophic cardiomyopathy in a large longitudinal cohort, approximately one-third developed limiting symptoms over 5 years. Impaired right ventricular stroke volume index was a novel, independent predictor of future heart failure and may help identify high-risk patients, with implications for management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.